Description of the goods or services required
Porton Biopharma (PBL) is undertaking an extensive programme of work to create a new ICT core infrastructure, following the approval of a five-year technical Strategy by the business, mid-2019. Beginning with a limited scope ‘Pilot’ phase, the primary hosting and network solutions, cyber-security controls and use-cases must be trialled and refined. The duration of the Pilot is expected to be circa 6 months.
Having been fully dependent on Public Health England (PHE) ICT services and infrastructure since its inception in 2015, it is strategically important for PBL to now establish a completely new and independent ICT operation.
The following technical strategy has been approved for implementation. Within the limited scope of a Pilot phase, ICT services organisations are invited to express an interest in designing, supplying and building this environment in close collaboration with a dedicated PBL team, on a fixed-price basis.
• HCI-based hosting platform – currently specified as Dell-EMC VxRail stretch-cluster.
• Physical network underlay (limited scope).
• Perimeter firewall (to be specified)
• SDN network overlay technology (circa 30 endpoints) – currently specified as Cisco’s SDA solution.
• Horizon VDI for application and desktop virtualisation (2 – 3 pilot application environments).
• MS Windows domain(s) dedicated to PBL – including all domain-related services and inter-domain trust for testing purposes.
• Coherent IDAM/RBAC ecosystem.
The Pilot infrastructure will form the basis of a broader enterprise ICT core infrastructure that will be built-out in subsequent programme phases.
PBL operates within a highly regulated pharmaceutical environment (within FDA and MHRA codes/guidance for GMP IT). Close collaboration with PBL and adherence to ITIL principles and local IT Infrastructure Qualification controls will be critical to ensure compliance with regulatory standards from day-one.